See more : Stanley Electric Co., Ltd. (6923.T) Income Statement Analysis – Financial Results
Complete financial analysis of InnoCan Pharma Corporation (INNPF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of InnoCan Pharma Corporation, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Shuz Tung Machinery Industrial Co., Ltd. (4537.TWO) Income Statement Analysis – Financial Results
- Movie Games S.A. (MOV.WA) Income Statement Analysis – Financial Results
- Bouvet ASA (0HDU.L) Income Statement Analysis – Financial Results
- UMW Holdings Berhad (4588.KL) Income Statement Analysis – Financial Results
- Brookfield Reinsurance Ltd. (BNRE.TO) Income Statement Analysis – Financial Results
InnoCan Pharma Corporation (INNPF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://innocanpharma.com
About InnoCan Pharma Corporation
InnoCan Pharma Corporation, a pharmaceutical company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Poland, France, and internationally. The company engages in the research and development of COVID-19 and other condition treatment by using CBD loaded exosomes; and CBD loaded liposomes. Its product includes CBD eye serum, CBD face oil, CBD face cream, CBD facial serum, CBD sleeping mask, CBD recovery lotion, and the Relief & Go spray. The company is also involved in the commercialization and sale of branded CBD integrated pharmaceutical and topical treatment products. InnoCan Pharma Corporation was incorporated in 2018 and is headquartered in Calgary, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 13.66M | 2.56M | 196.00K | 8.00K | 0.00 | 0.00 |
| Cost of Revenue | 1.68M | 452.00K | 75.00K | 5.00K | 23.53K | 0.00 |
| Gross Profit | 11.98M | 2.11M | 121.00K | 3.00K | -23.53K | 0.00 |
| Gross Profit Ratio | 87.71% | 82.34% | 61.73% | 37.50% | 0.00% | 0.00% |
| Research & Development | 1.80M | 1.53M | 1.40M | 1.37M | 368.00K | 534.00K |
| General & Administrative | 3.08M | 3.98M | 3.71M | 2.90M | 2.44M | 593.00K |
| Selling & Marketing | 10.91M | 2.86M | 2.50M | 337.00K | 194.00K | 39.00K |
| SG&A | 13.99M | 6.85M | 6.20M | 3.24M | 2.63M | 632.00K |
| Other Expenses | -7.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.18M | 8.37M | 7.60M | 4.73M | 3.00M | 1.17M |
| Cost & Expenses | 9.85M | 8.83M | 7.68M | 4.73M | 3.00M | 1.17M |
| Interest Income | 23.42K | 21.00K | 13.00K | 8.00K | 40.00K | 0.00 |
| Interest Expense | 0.00 | 2.00K | 13.00K | 5.23M | 334.00K | 26.00K |
| Depreciation & Amortization | 33.61K | 33.61K | 42.62K | 42.11K | 23.53K | 2.00M |
| EBITDA | -3.77M | -3.70M | -7.44M | -4.69M | -2.98M | 0.00 |
| EBITDA Ratio | -27.60% | -242.67% | -3,794.39% | -58,562.50% | 0.00% | 0.00% |
| Operating Income | 3.80M | -6.27M | -7.48M | -4.73M | -3.00M | -1.17M |
| Operating Income Ratio | 27.85% | -244.86% | -3,816.33% | -59,062.50% | 0.00% | 0.00% |
| Total Other Income/Expenses | -7.84M | 2.38M | -2.61M | -5.23M | -334.00K | 806.86K |
| Income Before Tax | -4.03M | -3.89M | -10.09M | -9.95M | -3.34M | -1.19M |
| Income Before Tax Ratio | -29.54% | -151.93% | -5,148.47% | -124,412.50% | 0.00% | 0.00% |
| Income Tax Expense | 214.00K | 1.00K | -31.00K | -166.30K | -148.86K | -161.14K |
| Net Income | -4.70M | -3.76M | -10.05M | -9.95M | -3.34M | -1.19M |
| Net Income Ratio | -34.41% | -147.09% | -5,126.02% | -124,412.50% | 0.00% | 0.00% |
| EPS | -0.02 | -0.02 | -0.04 | -0.06 | -0.02 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.04 | -0.06 | -0.02 | -0.01 |
| Weighted Avg Shares Out | 257.01M | 248.95M | 224.54M | 162.02M | 143.87M | 143.87M |
| Weighted Avg Shares Out (Dil) | 257.00M | 248.95M | 224.54M | 162.02M | 143.87M | 143.87M |
Innocan Exercises Option to Enter into a Research and License Agreement with Ramot the Commercial company of the Tel Aviv University
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 18, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce that, following the early indications of its CBD Loaded Exosomes platform (CLX),...
Innocan Pharma Updates its Progress in the Pre-Clinical Studies of its CBD-Loaded Liposome Platform (LPT)
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 3, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to issue an update on its cutting-edge pre-clinical studies and on the development progress...
Innocan Pharma Announces the Filing of a Patent Application for the Treatment and Prevention of Hair Loss
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - July 28, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") filed a patent application for its topical composition for hair loss treatment. The patent application discloses...
Former Israeli Minister of Science and Technology and Highly Influential Venture Capitalist to Join Innocan Pharma's Advisory Committee
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - July 14, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce the addition of Izhar Shay, Israel's former Minister of Science and Technology,...
Innocan Pharma Announces Filing of International Patent Application for Topical Treatment for Diabetic Symptoms
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - July 9, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") announces the filing of an international patent application for Topical Composition for the Treatment of Diabetic...
Innocan Pharma and Health Investment Group S.A. Sign Exclusive Distribution Agreement for Poland
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - July 1, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce that it has signed an exclusive distribution agreement with Health Investment Group...
Clinical Study Validates Innocan Pharma's SHIR(R) CBD Eye Serum as an Anti-Puffiness Solution
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - June 16, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce today that it has completed a cosmetic clinical study of SHIR® CBD...
Innocan Pharma Announces Patent Application for Novel Cannabis-Based Vaginal Moisturizer and Lubricant Treatment
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - June 14, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is honored to announce it has filed an international patent application for a novel cannabis-based Vaginal...
Innocan Pharma's Liposome Platform Technology Demonstrates a 7-Week Prolonged Release of CBD into Bloodstream in Recent Animal Study
Herzliya, Israel and Calgary Alberta--(Newsfile Corp. - June 11, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce that a recent study conducted on mice demonstrated a prolonged release of...
Innocan Pharma Among Leading CBD Pharma Companies to Participate at Lytham Partners Summer 2021 Investor Conference
Iris Bincovich, CEO will participate on the "CBD Treatments" discussion panel on Monday June 14 at 11:00AM ET.Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - June 9, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or...
Source: https://incomestatements.info
Category: Stock Reports